Last update 31 May 2025

HS-20122

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
HS-20122
Target
EGFR x c-Met
Action
modulators, inhibitors
Mechanism
EGFR modulators(Epidermal growth factor receptor erbB1 modulators), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Locally Advanced Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
Inactive Indication-
Originator Organization
Shanghai Hansoh Biomedical Co. Ltd.Shanghai Hansoh Biomedical Co. Ltd.
Active Organization
Changzhou Humon Pharmaceutical Co., Ltd.Shanghai Hansoh Biomedical Co. Ltd.Shanghai Hansoh Biomedical Co. Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with HS-20122
NCT06927570
/ Not yet recruitingPhase 1
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20122 in Patients With Advanced Solid Tumors
100 Clinical Results associated with HS-20122
Login to view more data
100 Translational Medicine associated with HS-20122
Login to view more data
100 Patents (Medical) associated with HS-20122
Login to view more data
100 Deals associated with HS-20122
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Malignant Solid NeoplasmPhase 1-
Shanghai Hansoh Biomedical Co. Ltd.Shanghai Hansoh Biomedical Co. Ltd.
09 May 2025
Advanced Malignant Solid NeoplasmPhase 1
China
Changzhou Humon Pharmaceutical Co., Ltd.
15 Apr 2025
Advanced Malignant Solid NeoplasmPhase 1
China
Shanghai Hansoh Biomedical Co. Ltd.Shanghai Hansoh Biomedical Co. Ltd.
15 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free